OPPM
ALNY icon

Opus Point Partners Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Opus Point Partners Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1.1M Buy
13,684
+333
+2% +$26.3K 1.99% 10
2019
Q2 		$969K Hold
13,351
– – 1.43% 16
2019
Q1 		$1.25M Sell
13,351
-904
-6% -$75.6K 1.69% 12
2018
Q4 		$1.04M Buy
14,255
+756
+6% +$58.1K 2.29% 11
2018
Q3 		$1.18M Sell
13,499
-613
-4% -$61.7K 2.82% 12
2018
Q2 		$1.39M Buy
14,112
+432
+3% +$42.8K 3.01% 9
2018
Q1 		$1.63M Sell
13,680
-29,384
-68% -$3.79M 3.2% 7
2017
Q4 		$5.47M Sell
43,064
-4,395
-9% -$552K 4.73% 6
2017
Q3 		$5.58M Sell
47,459
-1,636
-3% -$140K 5% 4
2017
Q2 		$3.92M Sell
49,095
-41,026
-46% -$2.62M 3.59% 8
2017
Q1 		$4.62M Buy
90,121
+1,337
+2% +$61.8K 3.43% 7
2016
Q4 		$3.32M Buy
88,784
+43,720
+97% +$1.83M 2.65% 12
2016
Q3 		$3.05M Buy
45,064
+1,380
+3% +$97.4K 1.71% 16
2016
Q2 		$2.42M Sell
43,684
-33,909
-44% -$2.14M 2.34% 18
2016
Q1 		$4.87M Buy
77,593
+27,371
+55% +$1.82M 3.77% 4
2015
Q4 		$4.73M Buy
50,222
+1,774
+4% +$164K 3.12% 14
2015
Q3 		$3.89M Buy
48,448
+13,469
+39% +$1.5M 2.15% 22
2015
Q2 		$4.19M Sell
34,979
-2,409
-6% -$288K 3.32% 14
2015
Q1 		$3.9M Buy
37,388
+19,513
+109% +$1.98M 3.27% 10
2014
Q4 		$1.73M Buy
+17,875
New +$1.66M 1.72% 25

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Opus Point Partners Management's ALNY Position: Q3 2019 in Review

Opus Point Partners Management increased its Alnylam Pharmaceuticals (ALNY) stake by 2.5% in Q3 2019, buying an estimated $26.3K and bringing the position to 13,684 shares worth $1.1M. The position accounts for 1.99% of the portfolio, ranked #10.

Opus Point Partners Management first reported a position in ALNY in Q4 2014 and has held it in 20 quarters since. The position peaked at $5.58M in Q3 2017. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

  • Opus Point Partners Management held 13,684 shares of Alnylam Pharmaceuticals worth $1.1M as of Q3 2019.
  • Opus Point Partners Management bought 333 Alnylam Pharmaceuticals shares in Q3 2019, an estimated $26.3K.
  • Alnylam Pharmaceuticals made up 1.99% of Opus Point Partners Management's portfolio in Q3 2019, its #10 holding.
  • Opus Point Partners Management first reported a position in Alnylam Pharmaceuticals in Q4 2014 and has held it in 20 quarters since.
  • Opus Point Partners Management's Alnylam Pharmaceuticals position peaked at $5.58M in Q3 2017.
  • 281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.